

Donald W Kufe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/355967/publications.pdf>

Version: 2024-02-01

218
papers

16,823
citations

14655

66
h-index

16183

124
g-index

221
all docs

221
docs citations

221
times ranked

12384
citing authors

#	ARTICLE	IF	CITATIONS
1	Mucins in cancer: function, prognosis and therapy. <i>Nature Reviews Cancer</i> , 2009, 9, 874-885.	28.4	1,148
2	Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. <i>Nature Medicine</i> , 1997, 3, 558-561.	30.7	575
3	p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. <i>Nature</i> , 1999, 399, 814-817.	27.8	551
4	Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors. <i>Hybridoma</i> , 1984, 3, 223-232.	0.6	502
5	Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. <i>Nature</i> , 1995, 376, 785-788.	27.8	496
6	Translocation of SAPK/JNK to Mitochondria and Interaction with Bcl-xL in Response to DNA Damage. <i>Journal of Biological Chemistry</i> , 2000, 275, 322-327.	3.4	384
7	Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. <i>Cancer Cell</i> , 2004, 5, 163-175.	16.8	309
8	Spatial and temporal control of gene therapy using ionizing radiation. <i>Nature Medicine</i> , 1995, 1, 786-791.	30.7	303
9	Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study. <i>Journal of the National Cancer Institute</i> , 1988, 80, 1039-1044.	6.3	301
10	Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. <i>Oncogene</i> , 2000, 19, 1975-1981.	5.9	284
11	Expression of the c-fms proto-oncogene during human monocytic differentiation. <i>Nature</i> , 1985, 316, 64-66.	27.8	278
12	Interaction of the DF3/MUC1 Breast Carcinoma-associated Antigen and β -Catenin in Cell Adhesion. <i>Journal of Biological Chemistry</i> , 1997, 272, 12492-12494.	3.4	278
13	Functional interaction between DNA-PK and c-Abl in response to DNA damage. <i>Nature</i> , 1997, 386, 732-735.	27.8	259
14	Interaction of Glycogen Synthase Kinase β with the DF3/MUC1 Carcinoma-Associated Antigen and β -Catenin. <i>Molecular and Cellular Biology</i> , 1998, 18, 7216-7224.	2.3	236
15	Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. <i>Nature</i> , 1996, 382, 272-274.	27.8	232
16	The Epidermal Growth Factor Receptor Regulates Interaction of the Human DF3/MUC1 Carcinoma Antigen with c-Src and β -Catenin. <i>Journal of Biological Chemistry</i> , 2001, 276, 35239-35242.	3.4	229
17	Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. <i>Cancer Cell</i> , 2005, 7, 167-178.	16.8	222
18	MUC1 Oncoprotein Blocks Glycogen Synthase Kinase β -Mediated Phosphorylation and Degradation of β -Catenin. <i>Cancer Research</i> , 2005, 65, 10413-10422.	0.9	206

#	ARTICLE	IF	CITATIONS
19	The c-Src Tyrosine Kinase Regulates Signaling of the Human DF3/MUC1 Carcinoma-associated Antigen with GSK3 β and β -Catenin. <i>Journal of Biological Chemistry</i> , 2001, 276, 6061-6064.	3.4	203
20	Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients. <i>Clinical Cancer Research</i> , 2013, 19, 3640-3648.	7.0	199
21	Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. <i>Nature Medicine</i> , 1997, 3, 437-442.	30.7	195
22	Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. <i>Oncogene</i> , 2003, 22, 6107-6110.	5.9	191
23	MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor β . <i>Molecular Cell</i> , 2006, 21, 295-305.	9.7	174
24	MUC1 oncoprotein activates the I κ B kinase β complex and constitutive NF- κ B signalling. <i>Nature Cell Biology</i> , 2007, 9, 1419-1427.	10.3	174
25	MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 205-215.	0.9	167
26	Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation. <i>Biochemistry</i> , 1992, 31, 8300-8306.	2.5	166
27	The MUC1 and Galectin-3 Oncoproteins Function in a MicroRNA-Dependent Regulatory Loop. <i>Molecular Cell</i> , 2007, 27, 992-1004.	9.7	165
28	Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. <i>Nature Medicine</i> , 1996, 2, 1367-1370.	30.7	164
29	MUC1-C Oncoprotein Functions as a Direct Activator of the Nuclear Factor- κ B p65 Transcription Factor. <i>Cancer Research</i> , 2009, 69, 7013-7021.	0.9	164
30	Determination of cell fate by c-Abl activation in the response to DNA damage. <i>Oncogene</i> , 1998, 17, 3309-3318.	5.9	160
31	Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. <i>Nature Medicine</i> , 1997, 3, 1145-1149.	30.7	158
32	The MUC1 Oncoprotein Activates the Anti-apoptotic Phosphoinositide 3-Kinase/Akt and Bcl-xL Pathways in Rat 3Y1 Fibroblasts. <i>Journal of Biological Chemistry</i> , 2004, 279, 20607-20612.	3.4	149
33	Human MUC1 Carcinoma Antigen Regulates Intracellular Oxidant Levels and the Apoptotic Response to Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2003, 278, 35458-35464.	3.4	148
34	Dependence on the MUC1-C Oncoprotein in Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 806-816.	4.1	144
35	Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. <i>Oncotarget</i> , 2016, 7, 11756-11769.	1.8	144
36	Activation of protein kinase C δ by the c-Abl tyrosine kinase in response to ionizing radiation. <i>Oncogene</i> , 1998, 16, 1643-1648.	5.9	143

#	ARTICLE	IF	CITATIONS
37	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. <i>Science Translational Medicine</i> , 2016, 8, 368ra171.	12.4	140
38	Activation of the Cytoplasmic c-Abl Tyrosine Kinase by Reactive Oxygen Species. <i>Journal of Biological Chemistry</i> , 2000, 275, 17237-17240.	3.4	138
39	Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells. <i>Cancer Research</i> , 2009, 69, 5133-5141.	0.9	132
40	Protein Kinase C ζ Regulates Function of the DF3/MUC1 Carcinoma Antigen in β -Catenin Signaling. <i>Journal of Biological Chemistry</i> , 2002, 277, 17616-17622.	3.4	131
41	MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1791-1801.	1.4	130
42	Targeting of the c-Abl Tyrosine Kinase to Mitochondria in Endoplasmic Reticulum Stress-Induced Apoptosis. <i>Molecular and Cellular Biology</i> , 2001, 21, 6233-6242.	2.3	121
43	Nuclear Import of the MUC1-C Oncoprotein Is Mediated by Nucleoporin Nup62. <i>Journal of Biological Chemistry</i> , 2007, 282, 19321-19330.	3.4	120
44	c-Abl Activation Regulates Induction of the SEK1/Stress-activated Protein Kinase Pathway in the Cellular Response to 1- β -D-Arabinofuranosylcytosine. <i>Journal of Biological Chemistry</i> , 1995, 270, 30278-30281.	3.4	108
45	Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1) β Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3. <i>Cancer Research</i> , 2008, 68, 2920-2926.	0.9	107
46	MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5837-5841.	7.1	106
47	Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. <i>Nature Medicine</i> , 1996, 2, 567-573.	30.7	103
48	Functional targeting of the MUC1 oncogene in human cancers. <i>Cancer Biology and Therapy</i> , 2009, 8, 1197-1203.	3.4	99
49	MUC1-Induced Transcriptional Programs Associated with Tumorigenesis Predict Outcome in Breast and Lung Cancer. <i>Cancer Research</i> , 2009, 69, 2833-2837.	0.9	98
50	MUC1 Oncoprotein Activates the FOXO3a Transcription Factor in a Survival Response to Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2004, 279, 45721-45727.	3.4	97
51	Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. <i>Gene</i> , 2006, 373, 28-34.	2.2	95
52	Targeting of the c-Abl Tyrosine Kinase to Mitochondria in the Necrotic Cell Death Response to Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2001, 276, 17281-17285.	3.4	93
53	Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. <i>Blood</i> , 2012, 119, 810-816.	1.4	93
54	Activation of MEK Kinase 1 by the c-Abl Protein Tyrosine Kinase in Response to DNA Damage. <i>Molecular and Cellular Biology</i> , 2000, 20, 4979-4989.	2.3	90

#	ARTICLE	IF	CITATIONS
55	Human Mucin 1 Oncoprotein Represses Transcription of the p53 Tumor Suppressor Gene. <i>Cancer Research</i> , 2007, 67, 1853-1858.	0.9	89
56	MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. <i>Nature Communications</i> , 2020, 11, 338.	12.8	87
57	MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. <i>EMBO Journal</i> , 2006, 25, 3774-3783.	7.8	84
58	MUC1-C Oncoprotein Promotes STAT3 Activation in an Autoinductive Regulatory Loop. <i>Science Signaling</i> , 2011, 4, ra9.	3.6	84
59	Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. <i>Cancer Research</i> , 2016, 76, 1538-1548.	0.9	84
60	Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. <i>Molecular Cancer Research</i> , 2003, 1, 765-75.	3.4	81
61	MUC1 Oncoprotein Functions in Activation of Fibroblast Growth Factor Receptor Signaling. <i>Molecular Cancer Research</i> , 2006, 4, 873-883.	3.4	80
62	MUC1 Oncoprotein Blocks Death Receptor-Mediated Apoptosis by Inhibiting Recruitment of Caspase-8. <i>Cancer Research</i> , 2008, 68, 6136-6144.	0.9	79
63	Transgene Expression in Malignant Glioma Using a Replication-Defective Adenoviral Vector Containing the Egr-1 Promoter: Activation by Ionizing Radiation or Uptake of Radioactive Iododeoxyuridine. <i>Human Gene Therapy</i> , 1998, 9, 1409-1417.	2.7	74
64	DF3/MUC1 Signaling In Multiple Myeloma Cells Is Regulated by Interleukin-7. <i>Cancer Biology and Therapy</i> , 2003, 2, 187-193.	3.4	72
65	MUC1-C Oncoprotein Activates ERK1/2 Signaling and Induction of Aldehyde Dehydrogenase 1A1 in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 30892-30903.	3.4	72
66	MUC1-C drives MYC in multiple myeloma. <i>Blood</i> , 2016, 127, 2587-2597.	1.4	71
67	Mucin 1 Oncoprotein Expression Is Suppressed by the miR-125b Oncomir. <i>Genes and Cancer</i> , 2010, 1, 62-68.	1.9	69
68	Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. <i>Journal of Gastroenterology</i> , 2001, 36, 764-771.	5.1	68
69	MUC1 oncoprotein is a druggable target in human prostate cancer cells. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3056-3065.	4.1	68
70	Genotoxic Drugs Induce Interaction of the c-Abl Tyrosine Kinase and the Tumor Suppressor Protein p53. <i>Journal of Biological Chemistry</i> , 1996, 271, 26457-26460.	3.4	64
71	Mucin 1 Oncoprotein Blocks Hypoxia-inducible Factor 1 α Activation in a Survival Response to Hypoxia. <i>Journal of Biological Chemistry</i> , 2007, 282, 257-266.	3.4	64
72	MUC1-C Oncoprotein Induces TCF7L2 Transcription Factor Activation and Promotes Cyclin D1 Expression in Human Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 10703-10713.	3.4	63

#	ARTICLE	IF	CITATIONS
73	MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 117-122.	7.4	62
74	Adenovirus Vector-Based Purging of Multiple Myeloma Cells. <i>Blood</i> , 1998, 92, 4591-4601.	1.4	61
75	Role for Lyn Tyrosine Kinase as a Regulator of Stress-Activated Protein Kinase Activity in Response to DNA Damage. <i>Molecular and Cellular Biology</i> , 2000, 20, 5370-5380.	2.3	60
76	Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non-Small Cell Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2014, 20, 5423-5434.	7.0	60
77	Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. <i>Oncotarget</i> , 2014, 5, 2622-2634.	1.8	59
78	Radiation Therapy-Induced Activation of Gene Transcription and the Development of Genetic Radiotherapy: Therapeutic Strategies in Oncology. <i>Cancer Biology and Therapy</i> , 2003, 2, 326-329.	3.4	58
79	Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. <i>Blood</i> , 2014, 123, 2997-3006.	1.4	58
80	Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. <i>International Journal of Oncology</i> , 2012, 40, 1643-9.	3.3	57
81	Novel Polymeric Nanoparticles for Intracellular Delivery of Peptide Cargos: Antitumor Efficacy of the BCL-2 Conversion Peptide NuBCP-9. <i>Cancer Research</i> , 2014, 74, 3271-3281.	0.9	56
82	MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. <i>BMC Medical Genomics</i> , 2010, 3, 16.	1.5	55
83	Function for p300 and not CBP in the apoptotic response to DNA damage. <i>Oncogene</i> , 1999, 18, 5714-5717.	5.9	54
84	c-Abl Tyrosine Kinase Regulates Caspase-9 Autocleavage in the Apoptotic Response to DNA Damage. <i>Journal of Biological Chemistry</i> , 2005, 280, 11147-11151.	3.4	54
85	MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. <i>Oncotarget</i> , 2014, 5, 8893-8905.	1.8	54
86	MUC1-C Induces the LIN28B-LET-7-HMGA2 Axis to Regulate Self-Renewal in NSCLC. <i>Molecular Cancer Research</i> , 2015, 13, 449-460.	3.4	53
87	MUC1-C Oncoprotein Regulates Glycolysis and Pyruvate Kinase m2 Activity in Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e28234.	2.5	53
88	MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. <i>Cancer Biology and Therapy</i> , 2003, 2, 702-6.	3.4	53
89	Oncogenic MUC1-C Promotes Tamoxifen Resistance in Human Breast Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 714-723.	3.4	52
90	Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. <i>British Journal of Haematology</i> , 2019, 185, 679-690.	2.5	52

#	ARTICLE	IF	CITATIONS
91	Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. JCI Insight, 2018, 3, .	5.0	52
92	Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. Clinical Cancer Research, 2015, 21, 2338-2347.	7.0	51
93	MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells. Oncogene, 2018, 37, 2079-2088.	5.9	50
94	MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells. Cancer Research, 2013, 73, 5569-5579.	0.9	49
95	Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 1744-1754.	4.1	49
96	MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. Carcinogenesis, 2020, 41, 1173-1183.	2.8	49
97	Regulation of c-jun gene expression in HL-60 leukemia cells by 1-beta-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanism. Biochemistry, 1991, 30, 7947-7952.	2.5	48
98	Targeting MUC1-C inhibits the AKT-S6K1-eIF4A pathway regulating TIGAR translation in colorectal cancer. Molecular Cancer, 2017, 16, 33.	19.2	48
99	Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS ONE, 2015, 10, e0135156.	2.5	47
100	Deoxycoformycin: Neurological toxicity. Cancer Chemotherapy and Pharmacology, 1981, 5, 193-196.	2.3	46
101	The MUC1-C Oncoprotein Binds to the BH3 Domain of the Pro-apoptotic BAX Protein and Blocks BAX Function. Journal of Biological Chemistry, 2012, 287, 20866-20875.	3.4	46
102	MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate, 2012, 72, 1659-1668.	2.3	46
103	MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells. Cancer Research, 2021, 81, 1111-1122.	0.9	46
104	Functional role for the c-Abl tyrosine kinase in meiosis. Oncogene, 1998, 16, 1773-1777.	5.9	45
105	MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells. Cancer Research, 2019, 79, 5711-5722.	0.9	45
106	A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells. Cancer Chemotherapy and Pharmacology, 2006, 59, 329-335.	2.3	44
107	Mucin 1 C-Terminal Subunit Oncoprotein Is a Target for Small-Molecule Inhibitors. Molecular Pharmacology, 2011, 79, 886-893.	2.3	44
108	MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. Oncoimmunology, 2017, 6, e1338998.	4.6	44

#	ARTICLE	IF	CITATIONS
109	Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1- β -D-arabinofuranosylcytosine. <i>Oncogene</i> , 1997, 15, 1947-1952.	5.9	42
110	Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells. <i>Oncogene</i> , 2000, 19, 3941-3947.	5.9	41
111	Dendritic cell fusion vaccines for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 703-715.	3.1	41
112	MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells. <i>Cancer Research</i> , 2007, 67, 11576-11584.	0.9	41
113	MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. <i>International Journal of Oncology</i> , 2009, 34, 1691-9.	3.3	41
114	MUC1-C integrates activation of the IFN- β pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. , 2021, 9, e002115.		41
115	MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. <i>Oncogene</i> , 2021, 40, 4930-4940.	5.9	41
116	Targeting the human MUC1 oncoprotein: A tale of two proteins. <i>Cancer Biology and Therapy</i> , 2008, 7, 81-84.	3.4	40
117	Interaction of human MUC1 and β -catenin is regulated by Lck and ZAP-70 in activated Jurkat T cells. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 471-476.	2.1	39
118	miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. <i>International Journal of Oncology</i> , 2010, 37, 61-9.	3.3	39
119	Cooperative Interaction between the MUC1-C Oncoprotein and the Rab31 GTPase in Estrogen Receptor-Positive Breast Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e39432.	2.5	39
120	MUC1-C activates EZH2 expression and function in human cancer cells. <i>Scientific Reports</i> , 2017, 7, 7481.	3.3	38
121	Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. <i>Cancer Biology and Therapy</i> , 2013, 14, 127-134.	3.4	37
122	Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. <i>Cancer Research</i> , 2002, 62, 789-95.	0.9	37
123	MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. <i>Scientific Reports</i> , 2016, 6, 26643.	3.3	36
124	MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. <i>Molecular Cancer Research</i> , 2016, 14, 1266-1276.	3.4	36
125	Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 13.	17.1	36
126	MUC1-C drives stemness in progression of colitis to colorectal cancer. <i>JCI Insight</i> , 2020, 5, .	5.0	36

#	ARTICLE	IF	CITATIONS
127	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 38974-38987.	1.8	36
128	Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein <scp>MUC</scp> 1. <i>British Journal of Haematology</i> , 2017, 176, 929-938.	2.5	34
129	Androgen receptor regulates expression of the MUC1â€™ oncoprotein in human prostate cancer cells. <i>Prostate</i> , 2011, 71, 1299-1308.	2.3	33
130	MUC1-C oncoprotein suppresses reactive oxygen speciesâ€™induced terminal differentiation of acute myelogenous leukemia cells. <i>Blood</i> , 2011, 117, 4863-4870.	1.4	33
131	2-(8-Hydroxy-6-methoxy-1-oxo-1â€™-2-benzopyran-3-yl)propionic Acid, a Small Molecule Isocoumarin, Potentiates Dexamethasone-Induced Apoptosis of Human Multiple Myeloma Cells. <i>Cancer Research</i> , 2004, 64, 8512-8516.	0.9	32
132	Survival of Human Multiple Myeloma Cells Is Dependent on MUC1 C-Terminal Transmembrane Subunit Oncoprotein Function. <i>Molecular Pharmacology</i> , 2010, 78, 166-174.	2.3	31
133	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. <i>Blood</i> , 2015, 126, 354-362.	1.4	31
134	1-beta-D-Arabinofuranosylcytosine Activates Tyrosine Phosphorylation of p34cdc2 and Its Association with the SRC-like p56/p53lyn Kinase in Human Myeloid Leukemia Cells. <i>Biochemistry</i> , 1995, 34, 1058-1063.	2.5	30
135	Dendritic Cells Induce MUC1 Expression and Polarization on Human T Cells by an IL-7-Dependent Mechanism. <i>Journal of Immunology</i> , 2005, 174, 2376-2386.	0.8	30
136	Inhibition of phorbol ester-induced monocytic differentiation by dexamethasone is associated with down-regulation of c-fos and c-jun (AP-1). <i>Journal of Cellular Physiology</i> , 1991, 149, 125-131.	4.1	29
137	Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells. <i>Journal of Cellular Physiology</i> , 1990, 143, 226-231.	4.1	28
138	A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 319-328.	2.3	28
139	MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells. <i>Cancer Research</i> , 2019, 79, 2031-2041.	0.9	28
140	Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. <i>Oncogene</i> , 1998, 17, 1889-1892.	5.9	27
141	Circulating Tumor Markers in Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1989, 3, 653-674.	2.2	27
142	Effects of dexamethasone on induction of monocytic differentiation in human U-937 cells by dimethylsulfoxide. <i>Journal of Cellular Physiology</i> , 1990, 142, 261-267.	4.1	24
143	Muc1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. <i>Cancer Biology and Therapy</i> , 2008, 7, 1959-1967.	3.4	24
144	MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. <i>International Journal of Oncology</i> , 2008, 33, 153-9.	3.3	23

#	ARTICLE	IF	CITATIONS
145	MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation. <i>Genes and Cancer</i> , 2010, 1, 239-250.	1.9	22
146	MUC1 in hematological malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 2489-2498.	1.3	22
147	Role of the MUC1 oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma. <i>Cancer Science</i> , 2020, 111, 3639-3652.	3.9	22
148	Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. <i>Cancer Biology and Therapy</i> , 2010, 10, 483-491.	3.4	21
149	A Monoclonal Antibody Against the Oncogenic Mucin 1 Cytoplasmic Domain. <i>Hybridoma</i> , 2011, 30, 531-535.	0.4	20
150	MUC1 is a target in lenalidomide resistant multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 914-926.	2.5	20
151	MUC1-C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS-Mediated Mechanism. <i>Genes and Cancer</i> , 2011, 2, 56-64.	1.9	19
152	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. <i>Haematologica</i> , 2021, 106, 1330-1342.	3.5	19
153	Stress response genes induced in mammalian cells by ionizing radiation. <i>Radiation Oncology Investigations</i> , 1993, 1, 81-93.	0.9	18
154	Strategies for enhancing viral-based gene therapy using ionizing radiation. <i>Radiation Oncology Investigations</i> , 1999, 7, 261-269.	0.9	17
155	Inhibition of c-Abl with STI571 Attenuates Stress-Activated Protein Kinase Activation and Apoptosis in the Cellular Response to 1- β -d-Arabinofuranosylcytosine. <i>Molecular Pharmacology</i> , 2002, 61, 1489-1495.	2.3	17
156	MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. <i>Oncogene</i> , 2019, 38, 7266-7277.	5.9	17
157	MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells. <i>Molecular Cancer Research</i> , 2022, 20, 556-567.	3.4	17
158	MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. <i>Oncolmmunology</i> , 2022, 11, 2029298.	4.6	17
159	MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. <i>Blood</i> , 2014, 123, 734-742.	1.4	16
160	Evolution of the human MUC1 oncoprotein. <i>International Journal of Oncology</i> , 2007, 31, 671-7.	3.3	16
161	Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin. <i>Cancer Chemotherapy and Pharmacology</i> , 1983, 10, 125-128.	2.3	14
162	Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 347-355.	2.3	14

#	ARTICLE	IF	CITATIONS
163	Evolution of the human MUC1 oncoprotein. <i>International Journal of Oncology</i> , 2007, 31, 671.	3.3	14
164	Anti-MUC1-C Antibody- α -Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1380-1389.	0.8	14
165	CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice. <i>Oncotarget</i> , 2017, 8, 78277-78288.	1.8	14
166	Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2580.	3.7	14
167	Inhibition of protein kinase C is associated with a decrease in myc expression in human myeloid leukemia cells. <i>FEBS Letters</i> , 1991, 294, 73-76.	2.8	13
168	Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1833-1839.	3.3	13
169	MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3887-3898.	3.6	12
170	Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 <i>In Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2215-2225.	4.1	10
171	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2304-2314.	4.1	10
172	The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. <i>Frontiers in Immunology</i> , 2021, 12, 735609.	4.8	10
173	MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas. <i>Carcinogenesis</i> , 2022, 43, 67-76.	2.8	10
174	Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment. <i>Oncogene</i> , 2022, 41, 3511-3523.	5.9	10
175	Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells. <i>Journal of Cancer Metastasis and Treatment</i> , 2022, 8, .	0.8	9
176	Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 69237-69249.	1.8	8
177	Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1379-1390.	3.4	8
178	Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. , 2020, 8, e000796.		7
179	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients. <i>Blood</i> , 2013, 122, 3928-3928.	1.4	7
180	A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 8, 301-4.	2.3	6

#	ARTICLE	IF	CITATIONS
181	Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 227-235.	4.2	6
182	Chemoinducible gene therapy. <i>Anti-Cancer Drugs</i> , 2005, 16, 1053-1058.	1.4	5
183	The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 610-614.	2.3	5
184	CBP501 suppresses macrophage induced cancer stem cell like features and metastases. <i>Oncotarget</i> , 2017, 8, 64015-64031.	1.8	5
185	Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer. <i>Theranostics</i> , 2022, 12, 999-1011.	10.0	5
186	Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.. <i>Blood</i> , 2004, 104, 751-751.	1.4	3
187	Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression. <i>Blood</i> , 2014, 124, 2072-2072.	1.4	3
188	A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. <i>Blood</i> , 2018, 132, 1446-1446.	1.4	2
189	CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model. <i>Blood</i> , 2019, 134, 1386-1386.	1.4	2
190	Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. <i>Blood</i> , 2019, 134, 392-392.	1.4	2
191	T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy. <i>Blood</i> , 2019, 134, 2673-2673.	1.4	2
192	Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. <i>Blood</i> , 2007, 110, 284-284.	1.4	2
193	MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2473-2473.	1.4	2
194	Diverse TNF α -induced death pathways are enhanced by inhibition of NF- κ B. <i>International Journal of Oncology</i> , 0, , .	3.3	1
195	Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy. <i>Blood</i> , 2018, 132, 2728-2728.	1.4	1
196	Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. <i>Blood</i> , 2010, 116, 848-848.	1.4	1
197	MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs. <i>Blood</i> , 2016, 128, 2871-2871.	1.4	1
198	MUC1-C drives DNA methylation in cancer. <i>Aging</i> , 2016, 8, 3155-3156.	3.1	1

#	ARTICLE	IF	CITATIONS
199	Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. <i>Blood</i> , 2019, 134, 3227-3227.	1.4	1
200	Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. <i>Blood</i> , 2021, 138, 2830-2830.	1.4	1
201	Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML. <i>Blood</i> , 2005, 106, 2788-2788.	1.4	0
202	Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Blood</i> , 2006, 108, 3080-3080.	1.4	0
203	Stimulation of Anti-Tumor Immunity Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28. <i>Blood</i> , 2006, 108, 3715-3715.	1.4	0
204	Stimulation of Anti-Tumor Immunity Using Dendritic Cells Transduced with Fowl Pox Vector Expressing MUC-1 and Costimulatory Molecules (PANVAC-F). <i>Blood</i> , 2006, 108, 5209-5209.	1.4	0
205	STAT3 Inhibition Promotes Potent Th1 Responses By Down Regulating Pdl-1 Expression On Tumor Cells. <i>Blood</i> , 2013, 122, 3217-3217.	1.4	0
206	Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential. <i>Blood</i> , 2013, 122, 127-127.	1.4	0
207	MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 808-808.	1.4	0
208	Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 2303-2303.	1.4	0
209	Myeloid-Derived Suppressor Cells Are Expanded in Patients with AML and Are Dependent on MUC1 Expression. <i>Blood</i> , 2014, 124, 226-226.	1.4	0
210	Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1. <i>Blood</i> , 2014, 124, 3378-3378.	1.4	0
211	MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells. <i>Blood</i> , 2015, 126, 643-643.	1.4	0
212	Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3659-3659.	1.4	0
213	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4175-4175.	1.4	0
214	Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells. <i>Blood</i> , 2016, 128, 703-703.	1.4	0
215	Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. <i>Blood</i> , 2019, 134, 3832-3832.	1.4	0
216	Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 904-904.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances. Blood, 2021, 138, 737-737.	1.4	0
218	Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial. Blood, 2020, 136, 10-10.	1.4	0